Search

Your search keyword '"Hao, Xishan"' showing total 538 results
Start Over Author "Hao, Xishan"
538 results on '"Hao, Xishan"'

2. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer

Author

Feng, Huijing, primary, Zhang, Siyuan, additional, Zhou, Qiuru, additional, Han, Fei, additional, Du, Gang, additional, Wang, Lin, additional, Yang, Xuena, additional, Zhang, Xiying, additional, Yu, Wenwen, additional, Wei, Feng, additional, Hao, Xishan, additional, Ren, Xiubao, additional, and Zhao, Hua, additional

Published
2024
Full Text
View/download PDF

6. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas

Author

Li, Hui, Yue, Dongsheng, Jin, Joy Q, Woodard, Gavitt A, Tolani, Bhairavi, Luh, Thomas M, Giroux-Leprieur, Etienne, Mo, Minli, Chen, Zhao, Che, Juanjuan, Zhang, Zhenfa, Zhou, Yong, Wang, Lei, Hao, Xishan, Jablons, David, Wang, Changli, and He, Biao

Subjects
Lung, Cancer, Lung Cancer, Orphan Drug, Rare Diseases, Biotechnology, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, Aetiology, A549 Cells, Adenocarcinoma, Adenocarcinoma of Lung, Animals, Antigens, CD, Antineoplastic Agents, Cadherins, Cell Movement, Epithelial-Mesenchymal Transition, Female, Gene Expression Regulation, Neoplastic, Hedgehog Proteins, Humans, Lung Neoplasms, Male, Mice, Nude, Middle Aged, Neoplasm Invasiveness, Signal Transduction, Smoothened Receptor, Time Factors, Tumor Burden, Xenograft Model Antitumor Assays, Zinc Finger Protein GLI1, sonic hedgehog, gli, epithelial-mesenchymal transition, lung cancer, adenocarcinoma, Oncology and Carcinogenesis
Abstract

Adenocarcinoma is the most common type of lung cancer. Epithelial-mesenchymal transition (EMT) is required for tumor invasion/metastasis and the components that control this process are potential therapeutic targets. This study we examined the role of Gli in lung adenocarcinoma and whether its activation regulates metastasis through EMT in lung adenocarcinoma. We found that tumors with high Gli expression had significantly lower E-Cadherin expression in two independent cohorts of patients with lung adenocarcinoma that we studied. In vitro up-regulation of SHh resulted in increased cell migration while small molecule inhibitors of Smo or Gli significantly reduced cell mobility both in a wound healing assay and in a 3D cell invasion assay. Inhibition of Gli in vivo decreased tumor growth and induced an increase in E-Cadherin expression. Our results indicate that Gli may be critical for lung adenocarcinoma metastasis and that a novel Gli inhibitor shows promise as a therapeutic agent by preventing cell migration and invasion in vitro and significantly reducing tumor growth and increasing E-Cadherin expression in vivo.

Published
2016

7. Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases

Author

Fang, Chihua, An, Jihyun, Bruno, Antonio, Cai, Xiujun, Fan, Jia, Fujimoto, Jiro, Golfieri, Rita, Hao, Xishan, Jiang, Hongchi, Jiao, Long R., Kulkarni, Anand V., Lang, Hauke, Lesmana, Cosmas Rinaldi A., Li, Qiang, Liu, Lianxin, Liu, Yingbin, Lau, Wanyee, Lu, Qiping, Man, Kwan, Maruyama, Hitoshi, Mosconi, Cristina, Örmeci, Necati, Pavlides, Michael, Rezende, Guilherme, Sohn, Joo Hyun, Treeprasertsuk, Sombat, Vilgrain, Valérie, Wen, Hao, Wen, Sai, Quan, Xianyao, Ximenes, Rafael, Yang, Yinmo, Zhang, Bixiang, Zhang, Weiqi, Zhang, Peng, Zhang, Shaoxiang, and Qi, Xiaolong

Published
2020
Full Text
View/download PDF

8. Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy

Author

Chen, Kexin, Yang, Da, Li, Xiangchun, Sun, Baocun, Song, Fengju, Cao, Wenfeng, Brat, Daniel J, Gao, Zhibo, Li, Haixin, Liang, Han, Zhao, Yanrui, Zheng, Hong, Li, Miao, Buckner, Jan, Patterson, Scott D, Ye, Xiang, Reinhard, Christoph, Bhathena, Anahita, Joshi, Deepa, Mischel, Paul S, Croce, Carlo M, Wang, Yi Michael, Raghavakaimal, Sreekumar, Li, Hui, Lu, Xin, Pan, Yang, Chang, Han, Ba, Sujuan, Luo, Longhai, Cavenee, Webster K, Zhang, Wei, and Hao, Xishan

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Oncology and Carcinogenesis, Biotechnology, Cancer, Breast Cancer, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Adenocarcinoma, Age Factors, Asian People, Case-Control Studies, China, DNA Mutational Analysis, Databases, Nucleic Acid, Disease-Free Survival, Female, Genome-Wide Association Study, Homologous Recombination, Humans, Male, Mutation, Neoplasm Proteins, Stomach Neoplasms, Survival Rate, clonality, exome sequencing, mutation, ERBB, BRCA2
Abstract

Gastric cancer (GC) is a highly heterogeneous disease. To identify potential clinically actionable therapeutic targets that may inform individualized treatment strategies, we performed whole-exome sequencing on 78 GCs of differing histologies and anatomic locations, as well as whole-genome sequencing on two GC cases, each with three primary tumors and two matching lymph node metastases. The data showed two distinct GC subtypes with either high-clonality (HiC) or low-clonality (LoC). The HiC subtype of intratumoral heterogeneity was associated with older age, TP53 (tumor protein P53) mutation, enriched C > G transition, and significantly shorter survival, whereas the LoC subtype was associated with younger age, ARID1A (AT rich interactive domain 1A) mutation, and significantly longer survival. Phylogenetic tree analysis of whole-genome sequencing data from multiple samples of two patients supported the clonal evolution of GC metastasis and revealed the accumulation of genetic defects that necessitate combination therapeutics. The most recurrently mutated genes, which were validated in a separate cohort of 216 cases by targeted sequencing, were members of the homologous recombination DNA repair, Wnt, and PI3K-ERBB pathways. Notably, the drugable NRG1 (neuregulin-1) and ERBB4 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 4) ligand-receptor pair were mutated in 10% of GC cases. Mutations of the BRCA2 (breast cancer 2, early onset) gene, found in 8% of our cohort and validated in The Cancer Genome Atlas GC cohort, were associated with significantly longer survivals. These data define distinct clinicogenetic forms of GC in the Chinese population that are characterized by specific mutation sets that can be investigated for efficacy of single and combination therapies.

Published
2015

11. Supplementary File from Integrated MicroRNA Network Analyses Identify a Poor-Prognosis Subtype of Gastric Cancer Characterized by the miR-200 Family

Author

Song, Fengju, primary, Yang, Da, primary, Liu, Ben, primary, Guo, Yan, primary, Zheng, Hong, primary, Li, Lian, primary, Wang, Tao, primary, Yu, Jinpu, primary, Zhao, Yanrui, primary, Niu, Ruifang, primary, Liang, Han, primary, Winkler, Hans, primary, Zhang, Wei, primary, Hao, Xishan, primary, and Chen, Kexin, primary

Published
2023
Full Text
View/download PDF

19. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4+ T cells through regulating type 2 conventional dendritic cells

Author

Luo, Jing, primary, Pang, Shuju, additional, Hui, Zhenzhen, additional, Zhao, Hua, additional, Xu, Shilei, additional, Yu, Wenwen, additional, Yang, Lili, additional, Sun, Qian, additional, Hao, Xishan, additional, Wei, Feng, additional, Wang, Jian, additional, and Ren, Xiubao, additional

Published
2023
Full Text
View/download PDF

24. The Senologic International Society Survey on Ductal Carcinoma In Situ: Present and Future

Author

Mathelin, Carole, Lodi, Massimo, Alghamdi, Khalid, Arboleda-Osorio, Bolivar, Avisar, Eli, Anyanwu, Stanley, Boubnider, Mohcen, Costa, Mauricio Maghales, Elder, Elisabeth, Elonge, Tony, Gebrim, Luiz, Hao, Xishan, Imoto, Shigeru, Meka, Esther, Mouelle, Michel, Mundinger, Alexander, Ostapenko, Valerijus, Özbaş, Serdar, Özmen, Tolga, Özmen, Vahit, Pienkowski, Tadeusz, Sarria, Gustavo, Selim, Ashraf, Semiglazov, Vladimir, and Schneebaum, Schlomo

Subjects
Original Article
Abstract

OBJECTIVE: Therapeutic management of ductal carcinoma in situ (DCIS) is heterogeneous among countries worldwide, and some treatment indications are still controversial. To investigate DCIS management in different countries; identify both consensual practices and controversial topics; and survey opinions about the future management of DCIS. MATERIALS AND METHODS: The Senologic International Society network members participated to an online survey using a questionnaire, between November 2021 and February 2022. RESULTS: Twenty-two responses from 20 different countries showed that organized breast cancer screening programs were present for 87% participants, and DCIS cases represented 13.7% of all breast cancers. Most participants used the grade classification (100%), the morphological classification (78%) and performed immunohistochemistry assays (73%). In case of conservative treatment, the mean re-excision rate was 10.3% and clear margins of mean 2.5 mm were considered healthy. Radical mastectomy rate was 35.5% with a breast reconstruction rate of 53%. Tumor bed boost indications were heterogeneous, and 73% of participants indicated hormone therapy for hormone-positive DCIS. Surgery and radiotherapy omission for some low-risk DCIS were considered by 73% of participants. Multigene assays were used by 43% of participants. Concerning future changes in DCIS management, participants mostly answered surgical de-escalation (48%), radiotherapy de-escalation (35) and/or active surveillance for some cases (22%). CONCLUSION: This survey provided an overview of the current practices of DCIS management worldwide. It showed that some areas are rather consensual: incidence increases over time, treatment in young women, pathological classifications, definition of healthy margins, the skin-sparing mastectomy and immediate breast reconstruction. However, some topics are still debated and result in heterogeneous practices, such as evolution in the age of diagnosis, the benefit of de-escalation in low-risk DCIS among elderly women, indications for hormone therapy, radiotherapy omission, or multigene assays. Further evidence is needed to reach consensus on these points, and innovative approaches are still under evaluation in clinical trials. The International Senologic Society, by its members, encourages precision medicine and personalized treatments for DCIS, to avoid overtreatment and overdiagnosis, and provide better healthcare to women with DCIS.

Published
2022

25. The Senologic International Society Survey on Ductal Carcinoma In Situ: Present and Future

Author

Mathelin, Carole, primary, Lodi, Massimo, additional, Alghamdi, Khalid, additional, Arboleda-Osorio, Bolivar, additional, Avisar, Eli, additional, Anyanwu, Stanley, additional, Boubnider, Mohcen, additional, Costa, Mauricio Maghales, additional, Elder, Elisabeth, additional, Elonge, Tony, additional, Gebrim, Luiz, additional, Hao, Xishan, additional, Imoto, Shigeru, additional, Meka, Esther, additional, Mouelle, Michel, additional, Mundinger, Alexander, additional, Ostapenko, Valerijus, additional, Özbaş, Serdar, additional, Özmen, Tolga, additional, Özmen, Vahit, additional, Pienkowski, Tadeusz, additional, Sarria, Gustavo, additional, Selim, Ashraf, additional, Semiglazov, Vladimir, additional, and Schneebaum, Schlomo, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results